Vilma Graupner
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Model-Based Meta-Analysis of Overall Survival in Vulnerable Platinum-Ineligible NSCLC Populations.
Journal: CPT: pharmacometrics & systems pharmacology
Published: July 28, 2025
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial.
Journal: Lancet (London, England)
Published: April 01, 2025
Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS Study.
Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS Study.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: March 31, 2025
CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 29, 2024
First-line atezolizumab monotherapy vs . single-agent chemotherapy in patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum-based therapy: Analysis of the IPSOS Asian subpopulation.
Journal: Chinese medical journal
Published: January 25, 2024
Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 28, 2022
Extension of the Alternative Intravenous Dosing Regimens of Atezolizumab into Combination Settings through Modeling and Simulation.
Journal: Journal of clinical pharmacology
Published: February 28, 2022
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: March 12, 2020
Showing 1-8 of 8
Last Updated: 09/26/2026